Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study
Neda Rajamand Ekberg, Ulrik Bodholdt, Andrei‐Mircea Catarig, Sergiu‐Bogdan Catrina, Katrine Grau, Cecilia Nagorny Holmberg, Boris Klanger, Søren Tang Knudsen
Abstract
Aims: As part of the SURE programme, SURE Denmark/Sweden aimed to study the real-world use of once-weekly (OW) semaglutide in adults with type 2 diabetes (T2D) in Denmark/Sweden. Methods: SURE Denmark/Sweden was an 30-week, prospective, multicentre, open-label, observational study, enrolling adults with T2D and 1 documented HbA 1c value 12 weeks before initiating semaglutide at their physician's discretion. Primary (change in HbA 1c ) and secondary (including change in body weight, glycaemic and weight-loss target achievement) endpoints were assessed between baseline and end of study (EOS). Results: Of the 331 patients initiating semaglutide, 282 (85%) completed the study on treatment. For the latter, estimated mean changes [95% confidence interval] in HbA 1c and body weight between baseline and EOS were -1.2 [-1.3; -1.1]%-points (-13 [-14; -12] mmol/mol) and -5.4 [-6.0; -4.7] kg (both p < 0.0001), respectively, with similar results in Denmark and Sweden. At EOS, 67.5% of patients achieved HbA 1c <7%; 49.4% achieved a weight reduction of 5%. Reported adverse events were consistent with the known safety profile of semaglutide. Conclusions: In routine clinical practice in Denmark/Sweden, use of OW semaglutide was associated with glycaemic and weight-loss benefits in a wide range of adults with T2D, supporting real-world use. ClinicalTrials.